Table 1.

Baseline characteristics of analyzed patients

Characteristicsn (%)
Number of patients20
Age
 Median (range), y40 (23-54)
Sex
 Female12 (60)
 Male8 (40)
Histological subtypes
 Nodular sclerosis16 (80)
 Mixed cellularity3 (15)
 Lymphocyte rich1 (5)
Frontline therapy received
 ABVD, 4 courses5 (25)
 ABVD, 6 courses15 (75)
 Radiotherapy after ABVD6 (30)
Response to frontline therapy
 Primary refractory11 (55)
 Relapsed
 CR ≤1 y5 (25)
 CR >1 y4 (20)
Number of previous treatments
 25 (25)
 3-414 (70)
 >41 (5)
 Median (range)3 (2-6)
Previous salvage therapy*
 IGEV16 (80)
 DHAP7 (35)
 Bv5 (25)
 BEACOPP1 (5)
 Radiotherapy1 (5)
Transplant
 Autologous HSCT5 (25)
At the time of Bv+Bs start
 Characteristics of disease
  ≥3 nodal sites involved12 (60)
  Extranodal involvement10 (50)
  Mediastinal bulky6 (30)
  Bone marrow involvement1 (5)
  LDH > normal limits7 (35)
  ESR >506 (30)
 Ann Arbor/Cotswold staging
  I-II6 (30)
  III-IV14 (70)
  B symptoms11 (55)
 ECOG-PS
  0-114 (70)
  ≥26 (30)
  • Values are n (%) unless otherwise noted.

  • ABVD, doxorubicin 25 mg/m2 IV on days 1 and 15, bleomycin 10 IU/m2 IV on days 1 and 15, vinblastine 6 mg/m2 IV on days 1 and 15, dacarbazine 375 mg/m2 IV on days 1 and 15; IGEV, ifosfamide 2000 mg/m2 IV on days 1 to 4, gemcitabine 800 mg/m2 IV on days 1 and 4, vinorelbine 20 mg/m2 IV on day 1, and prednisolone 100 mg orally on days 1 to 4; BEACOPP (escalated), bleomycin 10 UI/m2 IV on day 8, etoposide 200 mg/m2 IV on days 1 to 3, doxorubicin 35 mg/m2 IV on day 1, cyclophosphamide 1250 mg/m2 IV on day 1, vincristine 1.4 mg/m2 IV on day 8, procarbazine 100 mg/m2 orally on days 1 to 7, prednisone 40 mg/m2 orally on days 1 to 14; DHAP, cisplatin 100 mg/m2 by continuous IV infusion over 24 hours, followed by cytosine arabinoside IV in 2 pulses each at a dose of 2 g/m2 given 12 hours apart. Dexamethasone, 40 mg IV, was given on days 1 through 4; Bv, at a dosage of 1.8 mg/kg IV every 3 weeks for a median of 3 courses (range, 2-4); ECOG-PS, Eastern Cooperative Oncology Group–Performance Status; ESR, erythrocyte sedimentation rate; LDH, lactate dehydrogenase.

  • * Four patients received several lines of salvage therapy, before Bv+Bs regimen.

  • Stage I is defined as involvement of 1 nodal group or lymphoid organ; stage II is defined as involvement of 2 or more nodal groups on the same side of diaphragm; stage III is defined as involvement of nodal groups on both sides of the diaphragm; and stage IV is defined as disseminated involvement of 1 or more extralymphatic organs (eg, lung, bone) with or without any nodal involvement.